Article Details
Retrieved on: 2018-04-30 19:15:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div><b>BlackRock Inc</b>. boosted its position in Endocyte (NASDAQ:ECYT) by 223.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,138,791 shares of the biopharmaceutical company's stock after buying an ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here